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Introduction
Epigenetics is characterized by a wide range of changes that are reversible and orchestrate gene expression. Recent studies of the epigenome have shown that epigenetic modifications play a role in cancer physiopathology including hematologic malignancies (Smith, et al 2009) . In MM, DNA hypomethylation was reported as the predominant early change during myelomagenesis that is gradually transformed to DNA hypermethylation in relapsed cases and during the progression of the disease (Heuck, et al 2013 , Walker, et al 2010 .
Hypermethylation of GPX3, RBP1, SPARC and TGFBI genes was demonstrated to be associated with significantly shorter overall survival, independent of age, ISS score and adverse cytogenetics (Kaiser, et al 2013) . DNA methylation is regulated by DNA methyltransferases (DNMT) (Hollenbach, et al 2010) .
Decitabine (5-aza-2'-deoxycytidine) or 5-azacytidine are both FDA (U.S. Food and Drug Administration)-approved DNMT inhibitors for the treatment of myelodysplastic syndrome (MDS). 5-azacytidine is a ribonucleoside and decitabine is a deoxyribonucleoside. Decitabine is incorporated only in DNA whereas 5-azacytidine incorporates both in DNA and RNA including rRNAs, tRNAs, mRNAs and miRNAs (Hollenbach, et al 2010) . Once incorporated into DNA, 5-azacytidine and decitabine will lead to DNMTs depletion, DNA hypomethylation and DNA damage induction (Hollenbach, et al 2010) . Via incorporation into newly synthetized RNA, 5-azacytidine will interfere with the processing of RNAs inhibiting protein synthesis (Hollenbach, et al 2010) . We have recently reported the building of a DNA methylation score (DM Score) predicting for the efficacy of decitabine to eliminate MM cells (MMCs). Given that 5-azacitidine can incorporate in both DNA and RNA and block DNA methylation and RNA translation, we have currently investigated whether DM Score could also predict for MMCs sensitivity to 5-azacitidine.
Materials and methods

Human Myeloma Cell Lines (HMCLs) and primary multiple myeloma cells of patients.
Human myeloma cell lines XG-1, XG-2, XG-5, XG-6, XG-12, XG-13, XG-16, XG-19, XG-20, RPMI8226, LP1 and SKMM2 (HMCLs, N=12) were obtained as previously described Resources. MMCs were purified as previously published , Moreaux, et al 2012 and whole genome gene expression profiling assayed with Affymetrix U133 2.0 plus microarrays (Affymetrix, Santa Clara, CA, USA). Gene expression data were analyzed using our bioinformatics platforms Primary myeloma cells of 14 patients were cultured with or without graded concentrations of 5-azacitidine and MMC cytotoxicity evaluated using anti-CD138-PE mAb (Immunotech, Marseille, France) as described (Moreaux, et al 2012) .
Gene set enrichment analysis (GSEA)
We compared the gene expression levels from high DM Score versus low DM Score patients and picked up the genes which had significant different expression for Gene set enrichment analysis (GSEA).
Results and Discussion
The efficacy of DM Score to predict MMCs sensitivity to 5-azacitidine was investigated on 12 HMCLs with high or low DM Score. The 6 HMCLs with high DM Score exhibited a 3 fold higher 5-azacitidine sensitivity (P = 0.01; median IC50 = 2.43 µM; range: 1.12 to 8.25 µM) compared to the 6 ones with a low DM Score (median IC50 = 7.45 µM; range: 5.73 to 27.9) ( Figure 1A ). DM score could also predict for the ability of 5-azacytidine to eliminate patients' primary MMCs cultured together with their BM environment. The MMCs of patients with a high DM Score (n = 7) exhibited a significant 1.6 fold higher 5-azacytidine sensitivity compared to low DM Score patients (n = 7) (P < .05, Figure 1B) .
Thus, the DM Score, which was built using 47 genes whose expression is Thus, the higher sensitivity of MMCs of patients with a high DM Score to DNMT inhibitors could be explained by the fact these inhibitors are mainly active in cell cycling cells since incorporation into DNA is restricted to the Sphase (Hollenbach, et al 2010) , and also by a reduced drug export in MMCs of these patients, resulting in higher intracellular drug accumulation (Karahoca and Momparler 2013) . Furthermore, DM Score is significantly higher in patients with a high GEP-based proliferation index (Supplementary Figure   S3 ), emphasizing these data.
Clinical trials are ongoing to evaluate the safety of DNMTi as monotherapy or in combination with lenalidomide or dexamethasone in MM (Maes, et al 2013) and investigate the link between HM Score and response of MM patients to DNMTi could be promising.
In conclusion, the DM Score allows identification of MM patients who could benefit from treatment with two clinical grade DNMT inhibitors and the development of personalized treatment. 
Good prognos+c genes
Low DM Score High DM Score Figure 2 
